BioSpace News Archive

Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083

NDA for Ripretinib for the Treatment of Advanced GIST Accepted for Priority Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Approval and Launch - - INTRIGUE Pivotal Phase 3 Study of Ripretinib in Second-line GIST Expected to Complete Enrollment in the Second Half of 2020 - - Ended 2019 with Cash, Cash Equivalents and Marketable Securities of $579.6 Million - - Company to Host

FEP® to eliminate restrictions on prescription drug refills, waive pre-authorization, deductibles and copays for diagnostics, treatment

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the fourth quarter and full year 2019 after market close on Monday, March 16, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.

Catalent, Inc. announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present via virtual meeting at the Barclays Global Healthcare Conference at 10:15 a.m.

The first mobile CT scan cabin produced by Yangzhou Tailee Special Equipment Co Ltd has been put into use in a hospital in Huanggang, one of the worst hit cities by the coronavirus outbreak in Hubei province, to help with the battle against the epidemic.